We just received data on a new analyst forecast for $XRAY. Kevin Caliendo from UBS set a price target of 13.0 for XRAY.
To track analyst ratings and price targets for $XRAY, check out Quiver Quantitative's $XRAY forecast page.
Should you buy $XRAY?
Some analysts are better than others. To view the past performance of UBS, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$XRAY Price Targets
Multiple analysts have issued price targets for $XRAY recently. We have seen 9 analysts offer price targets for $XRAY in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Kevin Caliendo from UBS set a target price of $13.0 on 11/16/2026
- Lilia-Celine Lozada from JP Morgan set a target price of $10.0 on 11/06/2026
- Michael Petusky from Barrington Research set a target price of $13.0 on 10/26/2026
- Steven Valiquette from Mizuho set a target price of $12.0 on 10/22/2026
- Michael Cherny from Leerink Partners set a target price of $10.0 on 10/14/2026
- Jason Bednar from Piper Sandler set a target price of $12.0 on 10/09/2026
- Vik Chopra from BMO Capital set a target price of $10.0 on 09/17/2026
$XRAY Insider Trading Activity
$XRAY insiders have traded $XRAY stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XRAY stock by insiders over the last 6 months:
- MICHAEL J BARBER purchased 15,175 shares for an estimated $150,004
- BRIAN P MCKEON purchased 10,000 shares for an estimated $101,199
- BRIAN T GLADDEN purchased 9,985 shares for an estimated $99,999
- BETSY D HOLDEN purchased 10,086 shares for an estimated $99,692
- CLYDE HOSEIN purchased 6,500 shares for an estimated $64,902
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$XRAY Revenue
$XRAY had revenues of $836M in Q3 2026. This is a decrease of -7.52% from the same period in the prior year.
You can track XRAY financials on Quiver Quantitative's XRAY stock page.
You can access data on XRAY stock through the Quiver Quantitative API.
$XRAY Hedge Fund Activity
We have seen 201 institutional investors add shares of $XRAY stock to their portfolio, and 212 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 6,493,548 shares (+163.8%) to their portfolio in Q2 2026, for an estimated $68,896,544
- SOUTHPOINT CAPITAL ADVISORS LP removed 3,000,000 shares (-30.0%) from their portfolio in Q2 2026, for an estimated $31,830,000
- FULLER & THALER ASSET MANAGEMENT, INC. removed 2,923,158 shares (-23.0%) from their portfolio in Q3 2026, for an estimated $25,899,179
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 2,515,813 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $22,290,103
- FREESTONE GROVE PARTNERS LP removed 2,297,378 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $24,375,180
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 2,164,018 shares (-90.6%) from their portfolio in Q3 2026, for an estimated $19,173,199
- COOKE & BIELER LP removed 1,838,530 shares (-26.5%) from their portfolio in Q3 2026, for an estimated $16,289,375
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.